The term drug design describes the search of novel compounds with biological activity, on a systematic basis. In its most common form, it involves modification of a known active scaffold or linking known active scaffolds, although de novo drug design (i.e., from scratch) is also possible. Though highly interrelated, identification of active scaffolds should be conceptually separated from drug design. Traditionally, the drug design process has focused on the molecular determinants of the interactions between the drug and its known or intended molecular target. Nevertheless, current drug design also takes into consideration other relevant processes than influence drug efficacy and safety (e.g., bioavailability, metabolic stability, interaction with antitargets).This chapter provides an overview on possible approaches to identify active scaffolds (including in silico approximations to approach that task) and computational methods to guide the subsequent optimization process. It also discusses in which situations each of the overviewed techniques is more appropriate.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-1-4939-7756-7_1 | DOI Listing |
Vet Anaesth Analg
December 2024
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA; Kenneth L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA.
Objective: To model pharmacokinetics of three benzodiazepines and their metabolites in sheep.
Study Design: A nonblinded, prospective, experimental study.
Animals: A group of six adult Hampshire-Suffolk cross-bred sheep (three females, three castrated males), 73 ± 3 kg (mean ± standard deviation).
J Immunother Cancer
January 2025
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
Background: ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.
Methods: In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments.
Adv Drug Deliv Rev
January 2025
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia; School of Mathematical and Physical Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW 2109, Australia; Research Center for Translational Medicine, Sirius University of Science and Technology, 354340, Sochi, Russia; National Research Ogarev Mordovia State University, Saransk, Mordovia Republic 430005, Russia.
Once an exotic add-on to fluorescence microscopy for life science research, fluorescence lifetime imaging (FLIm) has become a powerful and increasingly utilised technique owing to its self-calibration nature, which affords superior quantification over conventional steady-state fluorescence imaging. This review focuses on the state-of-the-art implementation of FLIm related to the formulation, release, dosage, and mechanism of action of drugs aimed for innovative diagnostics and therapy. Quantitative measurements using FLIm have appeared instrumental for encapsulated drug delivery design, pharmacokinetics and pharmacodynamics, pathological investigations, early disease diagnosis, and evaluation of therapeutic efficacy.
View Article and Find Full Text PDFAm J Obstet Gynecol
January 2025
Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second, University Hospital, Sichuan University; Children's Medicine Key Laboratory of Sichuan Province, Chengdu; NMPA Key Laboratory for Technical Research on Drug Products in Vitro and in Vivo Correlation, Chengdu; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu; Chinese Evidence-based Medicine Center, West China Hospital, Sichuan Universit. Electronic address:
Background: While guidelines suggest administering antibiotics 12 to 18 hours after the rupture of membranes in term premature rupture of membranes (PROM) women, in practice, clinicians tend to initiate prophylactic antibiotics as soon as possible to avoid risk of infection.
Objective: This study aimed to assess whether early administration of prophylactic antibiotics for term premature rupture of membranes reduces the incidence of maternal and neonatal infections.
Study Design: This multi-center, prospective cohort study included women with term premature rupture of membranes.
Biomaterials
January 2025
The Key Laboratory for Chemical Biology of Fujian Province, The MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, and Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China; Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Xiamen Key Laboratory of Translational Medical of Digestive System Tumor, Zhongshan Hospital, Xiamen University, Xiamen 361004, China. Electronic address:
Enterohepatic circulation (EHC) is a critical biological process for the normal regulation of many endogenous biomolecules and the increased retention of various exogenous substances. The status of EHC is closely related to the ordinary functioning of several digestive organs. However, it remains a challenge to achieve in vivo real-time visualization of this process.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!